블로그

• [FDA, 200616] 키트루다, 고형암 환자 대상 허가 for the treatment of adult and pediatric patients with unresectable or metastatic tumor mutational burden-high (TMB-H) [≥10 mutations/megabase (mut/Mb)] solid tumors, as determined by an FDA-approved test, that blog.naver.com · 2020.06.30